Angiogenesis in autosomal-dominant polycystic kidney disease

Kidney International

Volumn 60, Issue 1, 2001, Pages 37-45

  Bello Reuss, E ^a   Holubec, K ^a   Rajaraman, S ^a  

^a John Sealy Hospital and John Sealy Annex   (United States)

Author keywords

Cysts; Genetic disorder; Inherited kidney disease; KDR; MMP 2; Progressive renal disease; Vascular endothelial growth factor

Indexed keywords

GELATINASE A; INTEGRIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; ANEURYSM; ANGIOGENESIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD VESSEL PERMEABILITY; CAPILLARY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY ANGIOGRAPHY; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 0034959984     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00768.x     Document Type: Article

References (37)

1. Autosomal-dominant polycystic kidney disease
2. Polycystic kidney disease
3. Cystic disease of the kidney
4. The arterial supply of the congenital polycystic kidney and its relation to the clinical picture
5. Angiography in polycystic disease of the kidneys
6. The importance of selective renal angiography in the diagnosis of polycystic kidney disease
7. Angiographic diagnosis of polycystic renal disease
8. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease
9. Plasma concentration of endothelin and arterial pressure in patients with ADPKD
10. The anatomy of the renin-secreting cell in adult polycystic kidney disease
11. Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis
12. Antiangiogenic tumour therapy: Will it work?
13. Molecular angiogenesis
14. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
15. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischaemia
16. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
17. The biology of vascular endothelial growth factor
18. Expression of vascular endothelial growth factor and it receptors in human renal ontogenesis and in adult kidney
19. Quantitative image analysis for immunocytochemistry and in situ hybridization
20. A role for CFTR in human autosomal-dominant polycystic kidney disease
21. Electrophysiological studies on primary cultures of proximal tubule cells
22. Organ preservation solutions increase endothelial permeability and promote loss of junctional proteins
23. Angiogenic factors in the development of diabetic iris neovascularization and retinopathy
24. The renal circulation
25. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase-2 fragment with integrin binding activity
26. Role of vascular endothelial growth factor in the regulation of angiogenesis
27. Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization
28. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitis fluid
29. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor
30. Localization of matrix metalloproteinase-2 MMP-2 to the surface of invasive cells by interaction with integrin αvβ3
31. Matrix metalloproteinase-2 in a murine model of Infantile-type polycystic kidney disease
32. Polycystin 1 is required for the structural integrity of blood vessels
33. Taxol inhibits progression of congenital polycystic kidney disease
34. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
35. Time to treat polycystic kidney diseases like the neoplastic disorders that they are